相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms
Mugdha Sharma et al.
ONCOLOGY LETTERS (2021)
De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance
Zi-Yuan Nie et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells
Puneet Agarwal et al.
CELL STEM CELL (2019)
Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling
Maja Kim Kuepper et al.
LEUKEMIA (2019)
STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets
Damian Szklarczyk et al.
NUCLEIC ACIDS RESEARCH (2019)
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
David M. Ross et al.
LEUKEMIA (2018)
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
Elodie M. Kuntz et al.
NATURE MEDICINE (2017)
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia
Alice Giustacchini et al.
NATURE MEDICINE (2017)
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
Rebecca Warfvinge et al.
BLOOD (2017)
Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells
Bin Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
Sheela A. Abraham et al.
NATURE (2016)
Heatmapper: web-enabled heat mapping for all
Sasha Babicki et al.
NUCLEIC ACIDS RESEARCH (2016)
Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia
David A. Irvine et al.
SCIENTIFIC REPORTS (2016)
Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL- positive chronic myeloid leukemia
Xian Zeng et al.
AUTOPHAGY (2015)
β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
A. M. Eiring et al.
LEUKEMIA (2015)
High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias
Joseph Y. Shin et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Clonal expansion capacity defines two consecutive developmental stages of long-term hematopoietic stem cells
Tatyana Grinenko et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling
Bin Zhang et al.
BLOOD (2013)
KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors
Amie S. Corbin et al.
CANCER RESEARCH (2013)
Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs
Stefania Stella et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Stem cell heterogeneity: implications for aging and regenerative medicine
Christa E. Muller-Sieburg et al.
BLOOD (2012)
Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia
Bin Zhang et al.
CANCER CELL (2012)
Hematopoietic Stem Cell Heterogeneity Takes Center Stage
Michael R. Copley et al.
CELL STEM CELL (2012)
Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through β-catenin signaling
Wenxia Su et al.
EXPERIMENTAL HEMATOLOGY (2012)
Endothelial and perivascular cells maintain haematopoietic stem cells
Lei Ding et al.
NATURE (2012)
Role of STAT3 in transformation and drug resistance in CML
Rajesh R. Nair et al.
FRONTIERS IN ONCOLOGY (2012)
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
Su Chu et al.
BLOOD (2011)
IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia Development
Damien Reynaud et al.
CANCER CELL (2011)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Low Level of C-Kit Expression Marks Deeply Quiescent Murine Hematopoietic Stem Cells
Yoshikazu Matsuoka et al.
STEM CELLS (2011)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Instruction of lineage choice by hematopoietic cytokines
Michael A. Rieger et al.
CELL CYCLE (2009)
Hematopoietic stem cell transplantation without irradiation
Claudia Waskow et al.
NATURE METHODS (2009)
Stem cells and niches: Mechanisms that promote stem cell maintenance throughout life
Sean J. Morrison et al.
CELL (2008)
Kit regulates maintenance of quiescent hematopoietic stem cells
Lina A. Thoren et al.
JOURNAL OF IMMUNOLOGY (2008)
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
Oliver Hantschel et al.
LEUKEMIA & LYMPHOMA (2008)
Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches
Agnieszka Czechowicz et al.
SCIENCE (2007)
Leukemia stem cells in a genetically defined murine model of blast-crisis CML
Sarah J. Neering et al.
BLOOD (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells
S Chu et al.
BLOOD (2004)
分享论文
